{"nctId":"NCT02284516","briefTitle":"A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)","startDateStruct":{"date":"2014-11-06","type":"ACTUAL"},"conditions":["Dry Eye Disease"],"count":711,"armGroups":[{"label":"Lifitegrast","type":"EXPERIMENTAL","interventionNames":["Drug: Lifitegrast"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Lifitegrast","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient-reported history of Dry Eye Disease in both eyes.\n* Use of over the counter artificial tears within the past 30 days.\n* A negative urine pregnancy test for females and willingness to use adequate birth control throughout the study.\n* Able and willing to comply with all study procedures.\n\nExclusion Criteria:\n\n* Presence of an ocular condition that could affect the study parameters such as active ocular infections, ocular inflammation, glaucoma, or diabetic retinopathy;.\n* Unwilling to stop wearing contact lenses during the study.\n* LASIK or other ocular surgical procedures within 12 months prior to or during the study.\n* Use of prohibited medications\n* Significant medical conditions that could affect the study parameters.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Patient-Reported Eye Dryness Score to Day 84","description":"Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":"17.08"},{"groupId":"OG001","value":"68.3","spread":"16.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30.7","spread":"28.01"},{"groupId":"OG001","value":"-37.9","spread":"28.85"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Patient-Reported Eye Dryness Score to Day 14 and Day 42","description":"Eye dryness score was scored on a Visual Analogue Scale (VAS) ranges from 0-100 (0=no discomfort; 100=maximal discomfort).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":"17.08"},{"groupId":"OG001","value":"68.3","spread":"16.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.0","spread":"22.40"},{"groupId":"OG001","value":"-22.9","spread":"25.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.9","spread":"25.99"},{"groupId":"OG001","value":"-33.2","spread":"27.42"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":354},"commonTop":["Instillation site irritation","Instillation site reaction","Dysgeusia"]}}}